Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Division of Kidney and Pancreas Transplantation, Department of Surgery, University of Miami, Miller School of Medicine, 1801 NW 9th Ave., 5th Fl., Miami, FL 33136, USA.
An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n = 88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1 mg/kg) (n = 27) or thymoglobulin alone (4-7 doses; 1 mg/kg) (n = 23). SPK recipients received daclizumab (two doses; 1 mg/kg) in addition to thymoglobulin (five doses; 1 mg/kg). The return of peripheral blood CD25+ cells was delayed for 45 d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.
© 2010 John Wiley & Sons A/S.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on